Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda.

Transactions of the Royal Society of Tropical Medicine and Hygiene - 1 Aug 2016

Riedel David J, Taylor Simone, Simango Raulina, Kiromera Athanase, Sebeza Jackson, Baribwira Cyprien, Musabeyezu Emmanuel

Abstract excerpt

BACKGROUND: Hepatitis C virus (HCV) treatment data in sub-Saharan Africa are limited. This study was to determine HCV sustained virologic response(SVR) at 24 weeks in patients undergoing HCV therapy in Kigali, Rwanda. METHODS: The paper presents data for all patients treated for HCV with ribavirin/interferon at King Faisal Hospital in Kigali, Rwanda, from 1 January 2007 to 31 December 2014. RESULTS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Hospitals

Share to Interferons

Share to Ribavirin

Share to Rwanda

Share to Viral Load

Source

Identifiers

PMID: 27618922
DOI: 10.1093/trstmh/trw055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda.PMID 27618922Read ↗

Risk factors for difficult-to-treat hepatitis C virus genotype 4r in Rwanda and implications for elimination in sub-Saharan Africa.Semantic proximity Read ↗

Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa.Semantic proximity Read ↗

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.Semantic proximity Read ↗

Risk factors for viral hepatitis C infection in Rwanda: Results from a Nationwide Screening ProgramSemantic proximity Read ↗

Direct-acting antiviral regimens and HCV treatment failure and re-treatment in sub-Saharan Africa.Semantic proximity Read ↗

Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C.Semantic proximity Read ↗

Micro-elimination of Hepatitis C virus (HCV) infection in the General Population Cohort in rural Uganda: long-term follow-up to assess feasibility and outcomes of a screening and treatment interventionSemantic proximity Read ↗

Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).Semantic proximity Read ↗

Diversity, geographical distribution and predictive factors of Hepatitis C virus genotypes and subtypes in Rwanda.Semantic proximity Read ↗

Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.Semantic proximity Read ↗

The Prevalence and Genotype Distribution of Hepatitis C Virus in Kenya: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Feasability and effectiveness of scaling up hepatitis-C treatment in West and Central Africa: the TAC ANRS 12311 clinical trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.